Fig. 1: Mean monthly eGFR for the first year of treatment in patients receiving CDK4/6 inhibitors vs. aromatase inhibitors alone. | npj Breast Cancer

Fig. 1: Mean monthly eGFR for the first year of treatment in patients receiving CDK4/6 inhibitors vs. aromatase inhibitors alone.

From: Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Fig. 1: Mean monthly eGFR for the first year of treatment in patients receiving CDK4/6 inhibitors vs. aromatase inhibitors alone.The alternative text for this image may have been generated using AI.

Average eGFR by month and 95% confidence interval bars are shown. There was no significant difference between mean eGFR at month 12 among recipients of abemaciclib (N = 67), palbociclib (N = 201), or aromatase inhibitors alone (N = 63); one-way ANOVA test p = 0.59. Ribociclib-treated patients were excluded from this analysis due to low numbers, only 6 survived to 12 months; shown in Supplemental Fig. 2. eGFR estimated glomerular filtration rate.

Back to article page